Among older adults in Spain, hospitalization rates from respiratory syncytial virus (RSV) infection increases progressively ...

Among older adults in Spain, hospitalisation rates from respiratory syncytial virus (RSV) infection increases progressively with age and is more ...

Participants were observed for two seasons, from August 31, 2021, to December 18, 2023, to evaluate vaccine efficacy, its safety and the increase in antibody levels against RSV-A and RSV-B variants.

MANILA, Philippines — Respiratory Syncytial Virus (RSV) is a common, contagious virus affecting the lungs and breathing ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to protect adults aged 60 years and older against lower ...

GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults: London, UK Saturday, March 8, 2025, 14:00 Hrs [IST] GSK plc will share its ...

Robust immune responses were observed among healthy and high-risk younger adults who received the Ad26/protein RSV preF vaccine.

A newly released white paper, based on research conducted independently by IQVIA, a global healthcare consultancy, and ...

indicated for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of age and older. The approval is based on data from ...

In the UK, RSV has an impact on elderly adults and is responsible for 175,000 GP appointments, 14,000 hospitalizations, and 8,000 deaths in adults 65 years of age and older per year.[i] "Given the ...

RSV, a common and contagious virus that affects the lungs and respiratory airways, that can affect people of all ages, from infants to adults. Among adults, it disproportionately affects older adults ...